Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Nuclear imaging of adrenal glands by slappypappy119

VIEWS: 84 PAGES: 2

									                                                                                                                 2005
OCTOBER 15–19 ’05 · ISTANBUL CONVENTION & EXHIBITION CENTRE · TURKEY



        1b

        Nuclear imaging of adrenal glands
        A. Kurtaran (Vienna)

        As a result of the increased use of radiological imaging modalities incidentally discovered adrenal
        masses (“incidentalomas”) have emerged as a clinical problem. In case of hormonally hyperactive adre-
        nal lesion(s) the most relevant question is whether one or both glands are involved. While radiological
        imaging procedures provide an excellent anatomical information, they may fail to give the answer in
        some cases. (,,3)
        In patients having non-secretory adrenal masses, however, attention must be paid to exclude a malig-
        nancy. Once a malignancy is proven, the evaluation of regional and distant metastatic spread has to be
        performed. This “staging “ procedure requires a whole body examination which makes nuclear imaging
        modalities attractive ().
        The standard nuclear imaging procedure of so-called chromaffin tumors is the iodine labeled MIBG-




                                                                                                                         Abstracts
        scintigraphy. The indications for MIBG scintigraphy are tissue characterization of incidentally detected
        adrenal lesion(s), the differentiation between unilateral pheochromocytoma and bilateral hyperplasia,
        and in case of extraadrenal disease the localisation of the underlying tumor site(s). This scintigraphic
        technique permits a non-invasive and accurate diagnosis of pheochromocytoma and paraganglioma,
        due to both its high sensitivity and specificity (,).
        Likewise, the adrenocortical scintigraphy mostly performed with 3I labeled 6ß-iodomethyl-norchole-
        sterol (NP-59), provides in vivo metabolic characterization of the adrenal glands based on the uptake of
        the radiotracer by functioning adrenal cortical tissue. One main indication for NP-59 scintigraphy is the
        in vivo depiction of the sites of abnormal hormonal secretion in case of hypersecretory adrenocortical
        syndromes (Cushing’s syndrome, primary aldosteronism, hyperandrogenism). In patients with primary
        aldosteronism, however, the adrenocortical scintigraphy should be performed with dexamethasone sup-
        pression for optimising the diagnostic sensitivity. Dexamethasone application has two important advan-
        tages: firstly, the differentiation between hyperplasia and adenoma, and secondly, the reduction of the
        radiation exposure to the normal adrenal gland.
        The other clinical indication for performing NP-59 scintigraphy is the tissue characterisation of inciden-
        talomas. Thereby, following relevant imaging patterns can be observed ():
        (a) “concordant” lesion: increased tracer uptake in the incidentaloma indicating a benign nature
        (b) “discordant” lesion: decreased/absent tracer uptake suspicious for malignancy
        Besides the traditional SPECT agents, recently a variety of PET-radiopharmeceuticals opened a new
        diagnostic dimension for metabolic characterisation of adrenal masses. As in oncology in general, the
        widely used tracer for the differential diagnosis of adrenal masses is 8F-FDG. Because of its relatively
        high sensitivity and specificity 8F-FDG whole body imaging is the standard PET imaging modality for
        detection of malignant tumor sites independent from its entity (4,5)
        Apart from this meanwhile well established PET tracer, new PET radipharmaceuticals have been introdu-
        ced. One of these is C-Metomitade, most promising to visualise masses of adrenocortical origin. While
        this PET technique seems to allow the differentiation between adrenocortical and non-cortical lesions,
        it is not appropriate to distinguish benign from malignant disease. As a consequence, FDG still remains
        tracer of choice for discriminating between benign and malignant lesions (5)
        In patients with adrenomedullary masses PET tracers may also be useful. 8F DOPA PET whole body is
        one of these techniques which was already shown to have an even higher sensitivity over MIBG scan.
        The main practical advantage of 8F DOPA PET over MIBG scintigraphy is the lack of uptake in normal
        adrenal glands implicating that any 8F DOPA uptake in the adrenals being abnormal. The specificity of
        8
          F DOPA PET seems to be similar to that of MIBG scintigraphy in those tumors (4).




                                                                                                                     9
                 ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE



                 References
                 . Kloos R.T, Gross M.D., I.R.. Korobkin, Francis M and Shapiro B. Incidentally discovered adrenal masses.
                     Endocrin. Rev 995;64: 460–484
                 . Kurtaran A, Traub T and Shapiro B. European Journal of Radiology 00; Volume 4, Issue ,
                     3-30
                 3. Copeland P.M., The incidentally discovered adrenal mass. Ann. Intern. Med. 98 983; 940–945
                 4. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP..
                     Scintigraphic imaging of the adrenal glands. Radiology. 00 Feb;():507-
                 5. Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Nieerle B, Dudczak R,
                     Kletter K. Positron emission tomography imaging of adrenal masses: 8F-fluorodeoxyglucose and
                     beta-hydroxylase tracer ()C-metomitade: Eur J Nucl Med Mol Imaging 004; 3(9):4-30
Abstracts




            0

								
To top